Results 281 to 290 of about 1,472,301 (348)

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update [PDF]

, 2018
et al,, Picus, Joel
core   +1 more source

Prognostic value of the prognostic nutritional index for patients with renal cell carcinoma: an update systematic review and meta-analysis. [PDF]

BMC Cancer
Xu Z, Xie L, Zhang H, Han G, Guo W.
europepmc   +1 more source

Sarcomatoid Renal Cell Carcinoma: Biological Features and Therapeutic Implications-A Narrative Review. [PDF]

Curr Urol Rep
Lasorsa F, Milella M, Rutigliano M, di Bari A, d'Amati A, Pandolfo SD, Bignante G, Caniglia A, Autorino R, Ditonno P, Lucarelli G.   +10 more
europepmc   +1 more source

Comparative optical characterization of renal cell carcinoma. [PDF]

Lasers Med Sci
Celik MB, Kucukkara I.
europepmc   +1 more source

Gamma-aminobutyric acid transaminase mediates tumor suppression in renal cell carcinoma through the cGAS-STING-interferon-β axis. [PDF]

Sci Rep
Feng Y, Cao S, Cai T, Lu Y, Jiang B, Lv Z, Tang J, Gao F, Zhao X, Liu C, Wang Q, Feng J, Wang Z, Ai Q, Cheng Q, Fan W, Li H.   +16 more
europepmc   +1 more source

Clear Cell Renal Cell Carcinoma with Synchronous Bladder Metastasis: Diagnostic, Surgical, and Pathological Insights from a Rare Presentation. [PDF]

J Clin Med
Benkova-Petrova M, Petrov A, Abushev P, Kirilov P, Marinov S, Malinova D, Stoeva-Grigorova S.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Renal Cell Carcinoma

Scandinavian Journal of Surgery, 2004
RENAL CELL CARCINOMA (RCC) accounts for approximately 3% of adult malignancy and 90% to 95% of neoplasms arising from the kidney. It is the sixth leading cause of cancer death in the United States. Approximately 31200 new cases of RCC were diagnosed in the United States in 2000 and more than 11900 affected individuals died.
Mirja, Ruutu, Börje, Ljungberg
  +7 more sources

Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma.

Urologic oncology, 2021
INTRODUCTION AND OBJECTIVE Unlike clear cell renal cell carcinoma (CCRCC), collecting duct carcinoma (CDC) and renal medullary carcinoma (RMC) are rare tumors that progress rapidly and appear resistant to current systemic therapies.
G. Bratslavsky, S. Gleicher, J. Jacob, Thomas Sanford, O. Shapiro, D. Bourboulia, L. Gay, Julie Andrea Elvin, J. Vergilio, J. Suh, S. Ramkissoon, E. Severson, J. Killian, A. Schrock, Jon H. Chung, V. Miller, M. Mollapour, J. Ross   +17 more
semanticscholar   +1 more source